Here, we show that the combination of the anti-CD4 depleting mAb with either PD-1 or PD-L1-blocking mAbs has anti-tumor synergistic effects, leading to 100% and 90% cure rates, in the Neuro2a model, respectively. Here, CD4 is linked to neoplasm.